Doc. Debora Karetová: Do Not Underestimate the Complexity of CHVO Treatment and Early Stages of the Disease
Are you applying the optimal approach to the treatment of chronic venous disease? What do the new Czech recommendations bring? And what is the current role of venopharmacs in treatment management? You can read all about this in an interview with the chair of the Czech Angiological Society ČLS JEP Doc. MUDr. Debora Karetová, CSc., from the 2nd Internal Clinic – Clinic of Cardiology and Angiology at the 1st Faculty of Medicine, Charles University, and General University Hospital in Prague.
What do the recommendations for the treatment of chronic venous diseases (CHVO) emphasize, and how has the perspective on them changed compared to the past?
In the treatment of chronic venous diseases, we strive for comprehensiveness and do not underestimate the early stages of the disease. On one hand, there is a high prevalence of this condition, affecting more than 50 percent of the population (of course, to varying degrees of severity), making it impossible to treat all patients. On the other hand, it is important to correctly identify symptomatic patients and initiate therapy in a timely manner. More than in the past, recommendations are based on
Did you like this article? Would you like to comment on it? Write to us. We are interested in your opinion. We will not publish it, but we will gladly answer you.
